** Trajan Group TRJ.AX jumps 8.6% to A$0.880, highest since May 27
** Stock set for its best day since March 12, if trend holds
** Life sciences products developer expects FY25 revenue to exceed upper-end of guidance at A$166.5 mln ($107.68 mln)
** Sees FY25 group EBITDA at A$15.5 mln, 8.8% below lower-end of guidance
** YTD, TRJ falls 22.1%
($1 = A$1.5463)
(Reporting by Keshav Singh Chundawat in Bengaluru)
((Keshav.SinghChundawat@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.